1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Enterovirus Infections - Pipeline Review, H1 2014

Enterovirus Infections - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 49 pages

Enterovirus Infections - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Enterovirus Infections - Pipeline Review, H1 2014’, provides an overview of the Enterovirus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterovirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterovirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Enterovirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Enterovirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Enterovirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Enterovirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Enterovirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Enterovirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Enterovirus Infections - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Enterovirus Infections Overview 7
Therapeutics Development 8
Pipeline Products for Enterovirus Infections - Overview 8
Pipeline Products for Enterovirus Infections - Comparative Analysis 9
Enterovirus Infections - Therapeutics under Development by Companies 10
Enterovirus Infections - Therapeutics under Investigation by Universities/Institutes 12
Enterovirus Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Enterovirus Infections - Products under Development by Companies 17
Enterovirus Infections - Products under Investigation by Universities/Institutes 18
Enterovirus Infections - Companies Involved in Therapeutics Development 19
Medigen Biotechnology Corporation 19
Sinovac Biotech Ltd. 20
Beijing Minhai Biotechnology Co., Ltd 21
Shanghai Zerun Biotechnology Co., Ltd. 22
Sentinext Therapeutics Sdn Bhd 23
Enterovirus Infections - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 30
Drug Profiles 32
EV-71 Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Enterovirus 71 Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
OBR-5-340 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Genetic EV71 Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Coxsackievirus A16 Vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Enterovirus-71 Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
KR-22809 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
TP-219 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
First Generation Vaccine for EV71 Infections - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Second Generation Vaccine for EV71 Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Enterovirus Infections - Recent Pipeline Updates 42
Enterovirus Infections - Dormant Projects 43
Enterovirus Infections - Product Development Milestones 44
Featured News and Press Releases 44
May 28, 2013: Experimental Vaccine Protects Kids Against Hand, Foot And Mouth Disease, Clinical Trial Shows 44
Nov 09, 2011: Sinovac Reports Positive Preliminary Phase II Clinical Trial Results For EV71 Vaccine Against Hand, Foot And Mouth Disease 44
Jun 28, 2011: Sinovac Commences Phase II Clinical Trial For EV71 Vaccine 45
May 25, 2011: Sinovac Reports Positive Phase I Clinical Trial Results For EV71 Vaccine Against HFMD 45
Mar 10, 2011: Sinovac Reports Positive Preliminary Phase I Clinical Trial Results For EV71 Vaccine In Adult Group 46
Dec 28, 2010: Sinovac Receives SFDA Approval To Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables

Number of Products under Development for Enterovirus Infections, H1 2014 8
Number of Products under Development for Enterovirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Enterovirus Infections - Pipeline by Medigen Biotechnology Corporation, H1 2014 19
Enterovirus Infections - Pipeline by Sinovac Biotech Ltd., H1 2014 20
Enterovirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 21
Enterovirus Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H1 2014 22
Enterovirus Infections - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2014 23
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 31
Enterovirus Infections Therapeutics - Recent Pipeline Updates, H1 2014 42
Enterovirus Infections - Dormant Projects, H1 2014 43

List of Figures

Number of Products under Development for Enterovirus Infections, H1 2014 8
Number of Products under Development for Enterovirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Molecule Type, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.